Weekly Longevity....by Klim - June 24 Week
Rapalogic, Midjourney, Ultrahuman and more
Longevity & Preventative Health
A factual scan of the past seven days across longevity, wellness, healthtech, AI-native clinical infrastructure, beauty, supplements, fitness, and hospitality.
Funding & M&A
Cadence raised a $100M Series C for tech-enabled remote care (June 23, 2026). The virtual chronic-care company, which combines remote patient monitoring and clinician-led management for cardiometabolic conditions (hypertension, type 2 diabetes, heart failure) across a national health-system network, said the round funds expansion of its care model and its move deeper into specialty and behavioral conditions. Verify note: confirm lead investor and post-money valuation against the company release and a second outlet before public citation. Source: company release; healthtech trade coverage.
ChartSpan acquired Validic to expand remote monitoring (June 22, 2026). ChartSpan, a large chronic-care-management services company, said the acquisition of Validic — a remote-patient-monitoring and device-data integration platform — lets it combine population-scale care coordination with continuous device data, a consolidation play in the RPM-plus-CCM stack. Verify note: deal terms were not disclosed in initial coverage. Source: company release; healthtech trade coverage.
Rapalogix Health raised a $20M Series A for rapamycin-based longevity medicine (June 23, 2026). The clinical-stage company is building protocols around rapamycin (an mTOR inhibitor with a deep preclinical aging literature) for healthy-aging and preventative use, pairing physician oversight with biomarker tracking. Verify note: single-source at time of writing; rapamycin for healthy aging remains off-label and clinically unproven for longevity endpoints; confirm lead investor and trial status. Source: venture funding roundup.
Clair Health raised an $11.6M seed round (June 17, 2026). The company is building AI-native infrastructure for preventative and longevity-oriented clinical care, positioning software as the connective layer between diagnostics, clinicians, and patients. Verify note: seed-stage and single-source; confirm investor syndicate and product scope. Source: venture funding roundup.
Prosper raised $30M to scale AI agents for healthcare operations (June 22, 2026). The company applies agentic AI to administrative and revenue-cycle workflows for providers, part of the broader move to push generative AI into the back office of care delivery rather than the clinical encounter itself. Verify note: confirm lead investor and that this is the healthcare-AI “Prosper” (the name is shared by several companies). Source: venture funding roundup.
My Lens / Pattern to watch
This week the money moved toward infrastructure and care delivery, not consumer brands: a $100M raise for remote cardiometabolic management, an RPM platform acquisition, two AI-native clinical-infrastructure rounds, and an agentic-AI play for healthcare operations. The thesis underneath is that the margin in longevity is shifting from the product you sell a consumer to the system that manages a chronic condition over years. I’d watch Rapalogix carefully — a funded, physician-branded rapamycin protocol is exactly the kind of thing that gets ahead of its own evidence, and the gap between “deep preclinical literature” and “proven in humans for aging” is where the reputational risk lives.
Breakthroughs & Research
Nature Medicine published organ-specific proteomic aging clocks naming brain and immune aging as the strongest healthspan predictors (reported mid-June 2026). Drawing on UK Biobank plasma proteomics (n≈44,500), researchers built biological-age estimates for roughly 11 organ systems and found that an accelerated brain age and an accelerated immune age were the sharpest predictors of future disease, mortality, and shortened healthspan — suggesting organ-level aging can be measured from a single blood draw and that the brain and immune system may be priority targets for intervention. Verify note: publication/coverage dated around June 15, 2026 — at or just before this window’s edge; confirm the exact publication date and journal issue before public citation. Observational cohort, not interventional. Source: Nature Medicine; UK Biobank; secondary science coverage.
My Lens / Pattern to watch
The commercial story writes itself: a single blood draw that scores the age of your brain and immune system, sold as the next panel above an epigenetic clock. The honest caveat is that this is association, not causation - knowing your immune system is “aging fast” does not yet come with a validated lever to slow it. I’d treat organ-clock proteomics as a powerful research and stratification tool and resist letting marketing turn a correlation into a promise. It’s a thinner research week than usual; I kept this section to the one defensible item rather than padding it.
New Openings
No clearly date-stamped premium longevity-clinic or destination-wellness opening surfaced inside the June 17–24 window. The category remains active — recent weeks brought Canyon Ranch’s Tucson Longevity Retreat and Life Time Paradise Valley (both carried in prior briefs).
New Launches
Midjourney unveiled a healthcare division and a full-body “Ultrasonic CT” scanner (June 17–18, 2026). The AI image-generation company announced Midjourney Medical: a whole-body ultrasound scanner that submerges a person in water and passes them through a ring of roughly half a million tiny ultrasonic transducers, producing a sub-millimeter 3D body map the company says rivals MRI at up to ~100x the speed, targeting a scan under 60 seconds with no radiation or magnetic fields. It paired this with a “Midjourney Spa” retail concept (hot tubs, saunas, cold plunges; a ~25,000-sq-ft San Francisco flagship slated for 2027) and stated ambitions of 50,000 scanners worldwide by 2031, reportedly backed by $74M+ of internal investment. Verify note: first-generation prototype with NO FDA clearance; the company says it will start with body-composition maps (which don’t require clearance) and layer on regulatory approvals incrementally. Performance figures are company claims, not peer-reviewed or independently validated. The Spa is a 2027 concept, not an open venue. Source: Midjourney; Bloomberg; Engadget; MobiHealthNews; Radiology Business; The BMJ.
Ultrahuman launched M2 Live, continuous real-time metabolic and recovery metrics on the wrist (June 18, 2026). The update pushes Ultrahuman’s data from after-the-fact summaries toward live, in-the-moment readouts — surfacing metrics continuously rather than as a morning report — extending the company’s positioning as a metabolic-and-longevity tracking platform rather than a sleep-and-activity ring. Verify note: confirm exact feature set, hardware vs. software scope, and market availability against Ultrahuman’s own release. Source: Ultrahuman; wearables trade coverage.
My Lens / Pattern to watch
Midjourney is the week’s most telling move: an AI company crossing into medical hardware and wrapping a preventative whole-body scan in spa aesthetics — the exact culture-meets-science-meets-luxury intersection where this market is heading. It is also a clean case study in claim-versus-clearance. A no-radiation, sub-60-second, MRI-rivaling scan is a stunning pitch; it is also an unvalidated prototype with no FDA clearance and “body composition only” at the start. The discipline is to separate the brand vision (spa-grade screening for everyone) from the regulatory reality (years of approvals between a prototype and a diagnosis). On the wrist, Ultrahuman’s “Live” shift makes the parallel point: continuous, in-the-moment metrics are a sharper engagement hook and a sharper anxiety risk. The open question across both: does more, faster data actually change outcomes — or just attention?
Conferences & Events
Forward-looking — confirmed events in the next 30 days.
Longevity Summit Dublin — June 24–26, Trinity College Dublin. Longevity science and biotech.
The Longevity Show + Scaling Health & Longevity Conference — June 26–27, Tobacco Dock, London. Consumer-plus-trade longevity festival, including a Women’s Health Summit track.
Healthy Longevity Talent Incubator (HLTI) — June 29 – July 10, National University of Singapore. Early-career healthy-longevity training program.
World Conference on Gerontology and Geriatrics — July 5–8, Amsterdam. Theme: aging well in a globalized world.
Opinion & Long Reads
The organ-clock coverage reopened the “biological age as a product” debate (mid-June 2026). Alongside the Nature Medicine proteomics work, science and consumer-health writers returned to a recurring question: as multi-organ aging clocks move from lab to blood panel, how should consumers interpret a number that predicts risk but doesn’t yet prescribe a fix? The useful framing in this coverage is the distinction between measurement and intervention — a theme worth holding onto as longevity testing commercializes. Verify note: this reflects a cluster of secondary commentary rather than a single landmark essay; confirm the specific piece you wish to cite. Source: secondary science and health commentary.
Wearables-to-clinic and real-time biometrics remained the live trade debate. Following Ultrahuman’s M2 Live and the continued push from Oura and Whoop into clinical-adjacent territory (carried last week), trade and enthusiast commentary kept circling the same tension: continuous, real-time data is a stronger engagement engine and a weaker clinical signal until it is validated and clinician workflows can absorb it. Verify note: ongoing trade-commentary thread, not a single primary report; cite the specific article before public use. Source: wearables trade and enthusiast coverage.
Other Notable News
FDA novel-approval watch (June 17–24, 2026). No novel-drug approvals in the obesity, cardiometabolic, or longevity categories were confirmed on FDA.gov within this seven-day window. Decisions still on watch include cytisinicline (smoking cessation; decision tracked for around late June) and veligrotug for thyroid eye disease (PDUFA June 30). Verify note: these are forthcoming PDUFA dates, not approvals; confirm any action directly on FDA.gov. Source: FDA.gov; Drugs.com.
Follow-up to last week: Colorado’s FDA-cleared Canadian drug-importation program (authorized June 15, 2026). The program — covering roughly 20 medicines reported to include Ozempic and Rinvoq — continued to draw coverage this week as a potential pressure point on U.S. cash-pay GLP-1 and specialty pricing. No material change to the authorization was confirmed in the window. Verify note: carried forward from last week’s brief; confirm any program updates on FDA.gov and state sources. Source: FDA; state coverage.
Source families: company releases and healthtech trade coverage (Cadence, ChartSpan/Validic); venture funding roundups (Rapalogix, Clair Health, Prosper); Nature Medicine / UK Biobank / secondary science coverage; Midjourney / Bloomberg / Engadget / MobiHealthNews / Radiology Business / The BMJ; Ultrahuman / wearables trade coverage; secondary science and health commentary; FDA.gov / Drugs.com; and named conference organizers (Longevity Summit Dublin, The Longevity Show, NUS HLTI, WCGG). Verification cutoff: June 24, 2026.